Xolair Pediatric Efficacy Discussion Slides Into Value Of Treatment
FDA's attempt to describe its internal assessment of "relatively modest" efficacy from the pediatric use of Novartis/Genentech's Xolair (omalizumab) during the Nov. 18 joint meeting of the Pulmonary & Allergy and Pediatric Drugs Advisory Committee opened up parts of the meeting to questions generally beyond the purview of regulatory decisions
You may also be interested in...
A post-market program designed by Novartis to control Xolair (omalizumab) in the 6-11 pediatric population was not adequate to convince FDA or its Pulmonary-Allergy Drugs Advisory Committee to extend the indication for use in moderate to severe allergy/asthma patients below 12 years of age
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials